Method and System to Provide Personalized Pharmaceutical Compositions and Dosages

摘要

Provided is a method for assessing cardiovascular risk in Metabolic Syndrome and Type 2 Diabetes patients. The method involves obtaining data from a Type 2 diabetes patient or a Metabolic Syndrome patient and determining a Fayad/Schentag index which includes a Glucose Supply Index (S) to an Insulin Demand Index (D) ratio. The Fayad/Schentag index is used in scoring cardiovascular risks of Metabolic Syndrome patients and for recommending and implementing therapeutic interventions that can be shown to lower cardiovascular risk

主权项

1. A method for determining cardiovascular risk for an individual suspected of having, at risk for, or diagnosed with a Metabolic Syndrome, the method comprising:
a) obtaining from the individual one or more biological parameters, and from the biological parameters: b) determining a Fayad/Schentag (FS) index, wherein the FS index is calculated as:0.11((FBG+TG)+HBA1c×HBA1c×205+BMI×FBG+TG150+AST×TG×4100+FBinsulin×(BMI-22))S/Dratio wherein the FBG is Fasting Blood Glucose in mg/dl; the TG is Triglycerides in mg/dl; the HBA1c is hemoglobin A1c in %; the BMI is body mass index in kg/m2; AST is Aspartate Transferase in IU/liter; FB insulin is fasting Blood insulin concentration in nmol/liter; and the S/D ratio (SD) is a ratio of Glucose Supply Index (S) to Insulin Demand Index (D) calculated as follows:
1+[aggregate of carbohydrate exposure (CE)+hepatic glucose uptake (HGU)+hepatic gluconeogenesis (GNG) and +insulin resistance (IR)], and (D) calculated as follows:
1+[aggregate of peripheral glucose uptake (PGU)+peripheral insulin exposure (PIE)]; c) assign the FS index determined in b) to the individual, wherein an FS index value of greater than 60 is indicative that the individual is in need of therapy for Metabolic Syndrome or at risk for at least one cardiovascular complication associated with Metabolic Syndrome.